samedan logo

 
 
spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

UK Medicines and Healthcare Products Regulatory Agency (MHRA) Issues an Early Access to Medicines Scheme (EAMS) Positive Scientific Opinion for Tepotinib for the Treatment of Advanced NSCLC with METex14 Skipping Alterations

Merck



Feltham (Merck)
– Merck announced today that the UK Medicines and Healthcare Products Regulatory Agency (MHRA) has issued an Early Access to Medicines Scheme (EAMS) positive scientific opinion for tepotinib for the treatment of adult patients with advanced Non-Small Cell Lung Cancer (NSCLC) harbouring mesenchymal-epithelial transition factor gene (MET) exon 14 (METex14) skipping alterations.1 With this approval, the MHRA have confirmed a positive benefit-risk ratio of tepotinib in this patient population.
 
The positive scientific opinion is based on results from the Phase II VISION study evaluating tepotinib as monotherapy in patients with advanced or metastatic NSCLC with METex14 skipping alterations, prospectively assessed by liquid biopsy or tissue biopsy. The VISION study demonstrated an objective response rate by independent review of 46% (95% confidence interval [CI], 36 to 57) in the combined-biopsy group. Data from the primary analysis of the VISION study were published in The New England Journal of Medicine (NEJM) on 29 May 2020.

Lung cancer is the third most common cancer in the UK, accounting for 13% of all new cancer cases in 2017, and was the leading cause of cancer related death in the UK in 2018. NSCLC is the most common type of lung cancer and accounts for approximately 80-85% of all lung cancer diagnoses.4 METex14 alterations occur in approximately 3-4% of NSCLC cases and generally exhibit a poorer clinical prognosis compared with other types of NSCLC. 

Dr Mike England, Medical Director, Merck UK & Ireland said: “We are delighted by the MHRA’s positive decision to provide early access to tepotinib for patients with advanced NSCLC harbouring METex14 skipping alterations in the United Kingdom, as there is a significant unmet need for new treatment options for these patients, who typically have a poor clinical prognosis. We believe this is a major advance in the treatment of these patients.
 
Tepotinib is not licensed in the United Kingdom for the treatment of advanced NSCLC with METex14 skipping alterations.  
phone +33 (0)5 57 960 960
email IECustomerrelations@merckgroup.com
web www.merckmillipore.com/GB/en
email 1 rue Jacques Monod, Site Montesquieu, 33650 Martillac, France
 
Print this page
Send to a friend
   
spacer
News and Press Releases

SHL attends the 2020 PDA in virtual fashion

SHL will join the 2020 Parenteral Drug Association’s annual Universe of Pre-Filled Syringes and Injection Devices virtual event with the launch of our virtual experience platform. Visitors can attend the event through the PDA’s online platform that comprises live chat sessions, conference presentations, and company pages.
More info >>


White Papers

High Containment FIBCs Offer a Safe and Cost Effective Alternative to their Rigid Counterparts

ILC Dover

As the need for powder containment and manufacturing in accordance with cGMP standards has grown over the years, companies have sought new alternatives to rigid IBCs. Recently high containment Flexible Intermediate Bulk Containers (FIBCs) have emerged which offer an alternative that provides both powder containment and the benefits of shipping with flexibles.
More info >>

Industry Events

Pharma Integrates 2021

16 November 2021, VIRTUAL CONFERENCE

Now in its tenth year, Pharma Integrates is a unique event bringing together pharma and healthcare leaders across the Pharmaceutical pipeline to address their needs, to share insights and create debate on crucial topics that influence the future of patient outcomes.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement